173 related articles for article (PubMed ID: 27573001)
21. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
[TBL] [Abstract][Full Text] [Related]
22. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
23. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
Sasaki A; Boyce BF; Story B; Wright KR; Chapman M; Boyce R; Mundy GR; Yoneda T
Cancer Res; 1995 Aug; 55(16):3551-7. PubMed ID: 7627963
[TBL] [Abstract][Full Text] [Related]
24. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases.
Hiraga T; Williams PJ; Mundy GR; Yoneda T
Cancer Res; 2001 Jun; 61(11):4418-24. PubMed ID: 11389070
[TBL] [Abstract][Full Text] [Related]
25. Oral administration of phytocomponent p-hydroxycinnamic acid has a preventive effect on bone loss in streptozotocin-induced diabetic rats.
Yamaguchi M; Uchiyama S; Lai YL
Int J Mol Med; 2007 May; 19(5):803-7. PubMed ID: 17390086
[TBL] [Abstract][Full Text] [Related]
26. Phytocomponent p-hydroxycinnamic acid inhibits osteoclast-like cell formation in mouse bone marrow cultures.
Lai YL; Yamaguchi M
Int J Mol Med; 2007 Jan; 19(1):123-8. PubMed ID: 17143556
[TBL] [Abstract][Full Text] [Related]
27. Parathyroid hormone-related protein and bone metastases.
Guise TA
Cancer; 1997 Oct; 80(8 Suppl):1572-80. PubMed ID: 9362424
[TBL] [Abstract][Full Text] [Related]
28. 15-deoxy-δ12,14-prostaglandin j2 inhibits osteolytic breast cancer bone metastasis and estrogen deficiency-induced bone loss.
Kim KR; Kim HJ; Lee SK; Ma GT; Park KK; Chung WY
PLoS One; 2015; 10(4):e0122764. PubMed ID: 25859665
[TBL] [Abstract][Full Text] [Related]
29. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.
Lee YP; Schwarz EM; Davies M; Jo M; Gates J; Zhang X; Wu J; Lieberman JR
Cancer Res; 2002 Oct; 62(19):5564-70. PubMed ID: 12359769
[TBL] [Abstract][Full Text] [Related]
30. Role of endothelin-1 in osteoblastic bone metastases.
Guise TA; Yin JJ; Mohammad KS
Cancer; 2003 Feb; 97(3 Suppl):779-84. PubMed ID: 12548575
[TBL] [Abstract][Full Text] [Related]
31. Macrophage migration inhibitory factor (MIF) inhibitor 4-IPP suppresses osteoclast formation and promotes osteoblast differentiation through the inhibition of the NF-κB signaling pathway.
Zheng L; Gao J; Jin K; Chen Z; Yu W; Zhu K; Huang W; Liu F; Mei L; Lou C; He D
FASEB J; 2019 Jun; 33(6):7667-7683. PubMed ID: 30893559
[TBL] [Abstract][Full Text] [Related]
32. Bone metastasis in breast cancer: the story of RANK-ligand.
Azim HA; Kamal NS; Azim HA
J Egypt Natl Canc Inst; 2012 Sep; 24(3):107-14. PubMed ID: 22929916
[TBL] [Abstract][Full Text] [Related]
33. Bone metabolic markers in bone metastases.
Koizumi M; Yamada Y; Takiguchi T; Nomura E; Furukawa M; Kitahara T; Yamashita T; Maeda H; Takahashi S; Aiba K
J Cancer Res Clin Oncol; 1995; 121(9-10):542-8. PubMed ID: 7559734
[TBL] [Abstract][Full Text] [Related]
34. Short-Term Hypoxia Accelerates Bone Loss in Ovariectomized Rats by Suppressing Osteoblastogenesis but Enhancing Osteoclastogenesis.
Wang G; Wang J; Sun D; Xin J; Wang L; Huang D; Wu W; Xian CJ
Med Sci Monit; 2016 Aug; 22():2962-71. PubMed ID: 27550548
[TBL] [Abstract][Full Text] [Related]
35. Osteoblastogenesis and osteoprotection enhanced by flavonolignan silibinin in osteoblasts and osteoclasts.
Kim JL; Kang SW; Kang MK; Gong JH; Lee ES; Han SJ; Kang YH
J Cell Biochem; 2012 Jan; 113(1):247-59. PubMed ID: 21898547
[TBL] [Abstract][Full Text] [Related]
36. Prevention of bone loss after ovariectomy in mice with preferential overexpression of the transcription factor paired box-5 in osteoblasts.
Fujita H; Hinoi E; Watanabe T; Iezaki T; Takamori M; Ogawa S; Yoneda Y
Biol Pharm Bull; 2013; 36(3):481-4. PubMed ID: 23449333
[TBL] [Abstract][Full Text] [Related]
37. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
38. Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo.
Chantry AD; Heath D; Mulivor AW; Pearsall S; Baud'huin M; Coulton L; Evans H; Abdul N; Werner ED; Bouxsein ML; Key ML; Seehra J; Arnett TR; Vanderkerken K; Croucher P
J Bone Miner Res; 2010 Dec; 25(12):2633-46. PubMed ID: 20533325
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological evidence for the bone-autonomous contribution of the NFκB/β-catenin axis to breast cancer related osteolysis.
Marino S; Bishop RT; Logan JG; Mollat P; Idris AI
Cancer Lett; 2017 Dec; 410():180-190. PubMed ID: 28965856
[TBL] [Abstract][Full Text] [Related]
40. Orthosilicic acid, Si(OH)4, stimulates osteoblast differentiation in vitro by upregulating miR-146a to antagonize NF-κB activation.
Zhou X; Moussa FM; Mankoci S; Ustriyana P; Zhang N; Abdelmagid S; Molenda J; Murphy WL; Safadi FF; Sahai N
Acta Biomater; 2016 Jul; 39():192-202. PubMed ID: 27163405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
